ArticleFrontiers in endocrinology2025
Trends in the global burden of gout attributable to kidney dysfunction, 1990-2021: a population-based analysis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout, primarily driven by hyperuricemia, is a prevalent inflammatory arthritis with kidney dysfunction being a significant risk factor. This study aims to comprehensively evaluate the global burden of gout attributable to kidney dysfunction from 1990 to 2021, highlighting differences across regions, genders, Socio-Demographic Index (SDI) levels, and age groups. Methods: Using data from the Global Burden of Disease (GBD) 2021 study, we assessed the burden of gout due to kidney dysfunction using disability-adjusted life years (DALYs) and years lived with disability (YLDs). Kidney dysfunction was defined as an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² or an albumin-to-creatinine ratio (ACR) ≥30 mg/g. The data were stratified by region, country, gender, age, and SDI quintiles. The annual percentage change (EAPC) was calculated to determine temporal trends. Results: From 1990 to 2021, global DALYs and YLDs attributable to gout due to kidney dysfunction increased significantly, rising from 78,564.8 years (95% uncertainty interval 48,687.9-118,061.9) to 200,033.3 years (125,245.0-296,812.4), a 2.5-fold increase. The age-standardized DALY rate (ASDR) and age-standardized YLD rate both increased, from 2.1 per 100,000 population in 1990 to 2.4 per 100,000 in 2021. DALY and YLD rates were consistently higher in males than in females. High SDI countries, especially North America and Australasia, had the most significant rise in burden, whereas low SDI regions experienced a decline. The burden increased with age, particularly in those aged 60 and above. Interpretation: This study underscores the substantial increase in the global burden of gout attributable to kidney dysfunction, particularly among the elderly, males, and populations in high SDI regions. The observed trends are driven by multiple factors, including lifestyle and dietary habits, diagnostic capacity, and demographic shifts. Future efforts should focus on improving surveillance and access to care in low-SDI regions to address potential underestimation of the burden. High-SDI regions should prioritize personalized health management strategies for the elderly, emphasizing early detection and intervention for gout and kidney dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.